Annovis Bio, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Annovis is a clinical-stage biotechnology company developing buntanetap for neurodegenerative diseases, including Parkinson’s disease (PD) and Alzheimer’s disease (AD). It has no product revenue and expects no product sales revenue in the foreseeable future.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Revenue | None | None reported |
| Research and development expense | $6.51 million | $7.79 million; down $1.27 million |
| General and administrative expense | $1.29 million | $2.18 million; down $0.89 million |
| Total operating expenses / operating loss | $7.81 million | $9.97 million |
| Net loss | $1.07 million | $9.74 million |
| Net loss per share, basic | $0.10 | $1.19 |
| Cash used in operating activities | $7.03 million | $11.63 million |
| Cash from financing activities | $4.42 million | $0.01 million |
Q1 2024 net loss included a $6.70 million noncash gain from remeasuring liability-classified warrants, largely associated with the decline in the company’s share price. This reduced the reported net loss; operating loss was $7.81 million. The filing reports diluted loss per share of $0.72, reflecting the warrant-related accounting treatment and incremental shares; investors should distinguish it from basic loss per share.
At March 31, 2024, cash and cash equivalents were $3.14 million, total current assets $7.81 million, current liabilities $4.87 million, and total liabilities $11.17 million. The balance sheet reports a $6.30 million warrant liability and a $3.35 million stockholders’ deficit. No borrowings or debt balance are reported in the supplied financial statements. Prepaid expenses and other current assets were $4.68 million, including $4.36 million in prepaid clinical expenses. No meaningful operating margin is available because the company had no revenue.
Material changes and liquidity
- Operating expenses fell year over year, mainly because of lower clinical-trial spending and lower stock-based compensation; management attributed clinical spending changes primarily to study-cost timing. Lower professional fees also reduced G&A expense.
- Operating cash use declined by $4.59 million year over year, mainly due to the timing of clinical-trial payments. Cash declined $2.62 million during Q1.
- Q1 financing included $3.88 million net proceeds from common-stock issuance and $0.54 million from warrant exercises. The March registered direct offerings generated $3.88 million net proceeds in aggregate.
- In May 2024, the company reported approximately $0.8 million net proceeds from its equity-line facility (ELOC), after issuing approximately 150,000 shares. The April ELOC agreement permits sales of up to 2,051,428 shares, subject to limitations, and provides for $375,000 in commitment shares.
Management said cash available, including May ELOC proceeds, was expected to fund operations into the fourth quarter of 2024. The company stated it lacks sufficient capital for the next 12 months and needs substantial additional financing. Management concluded that substantial doubt exists about the company’s ability to continue as a going concern; its financing and potential expense-deferral plans do not alleviate that doubt. Failure to secure capital could require a reduction in operations.
Outlook, developments, and risks
- The Phase 3 PD study was completed in December 2023 and unblinded in May 2024. The company expected to release topline efficacy data in June 2024.
- The Phase 2/3 AD study was completed in February 2024; the company announced data in April 2024 and planned to discuss it with the FDA, seek an end-of-Phase 2 meeting, and pursue a further Phase 3 study focused on biomarker-positive early AD patients.
- Management’s stated goal was to conduct required pivotal studies by the end of 2026 to support two potential new drug applications. These are plans, not assured outcomes.
- Key risks include clinical efficacy and safety, regulatory approval, reliance on external trial vendors, and the need for additional capital on acceptable terms. The company has not achieved profitability or positive operating cash flow. It reported no pending legal actions at March 31, 2024 and no material changes to the risk factors in its 2023 Form 10-K.
- The CFO ceased serving on April 30, 2024; the CEO became interim principal financial officer. The filing estimates maximum aggregate executive severance payments of $1.34 million at quarter-end and separately describes up to $65,500 payable to the former CFO under his separation agreement.
Important facts for investors to verify
- Current cash runway, subsequent ELOC proceeds and share issuance, and the company’s access to additional financing.
- Topline Phase 3 PD results and the full AD-study data, including clinical significance, safety, and planned FDA interactions.
- Potential dilution from the ELOC, outstanding options and warrants, and the warrant liability’s valuation sensitivity to stock-price assumptions.
- Whether trial timing, projected pivotal studies, and the goal of filing two NDAs by 2026 remain achievable.